Garczyk S et al. have demonstrated that NMU may contribute to the progression of NMUR2-positive breast cancer [21] and enhance resistance to tumor immune responses in breast cancers with HER2 overexpression [22], suggesting NMU is a potential drug target for personalized strategies. Here, ERBB2 is linked to breast carcinoma.